Overview

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Status:
Not yet recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a assay consisting of 5 CpGs: cg00396667（PITX1）, cg18815943 （FOXE3）, cg03890877（TWF2）, cg07611000 （EHBP1L1）and cg14391855（RIN1）that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Harzard Ratio(HR) of 4.93. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group.Disease free survival and overall survival are the end points of observation.

Phase:

N/A

Details

Lead Sponsor:

First Affiliated Hospital, Sun Yat-Sen University

Collaborators:

Health Science Center of Xi'an Jiaotong University
Health Science Center of Xi’an Jiaotong University
Sun Yat-sen University
Yantai Yuhuangding Hospital

Treatments:

Sunitinib